Evaluation of novel human immunodeficiency virus type 1 Gag DNA vaccines for protein expression in mammalian cells and induction of immune responses

被引:75
|
作者
Qiu, JT
Song, RJ
Dettenhofer, M
Tian, CJ
August, T
Felber, BK
Pavlakis, GN
Yu, XF
机构
[1] NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA
[2] Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA
[3] Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA
关键词
D O I
10.1128/JVI.73.11.9145-9152.1999
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Human immunodeficiency virus (HIV)-specific cytotoxic T lymphocytes (CTL) are an important parameter of host defenses that limit viral replication after infection. Induction of effective CTL against conserved viral proteins such as Gag may be essential to the development of a safe and effective HIV type 1 (HIV-1) vaccine. DNA vaccination represents a novel strategy for inducing potent CD8(+) CTL responses in vivo. However, expression of HIV-1 structural proteins by DNA vectors has been hampered by a stringent requirement for coexpression with other viral components, such as Rev and RRE. Furthermore, even with Rev and RRE present, the level of expression of HIV-1 Gag, pol, or Env is very low in murine cells. These problems have limited our ability to address the key issue of how to generate effective CTL responses to Gag in a mouse model. To overcome this problem, we compared several novel DNA expression vectors for HIV-1 Gag protein expression in primate and mouse cells and for generating immune responses in mice after DNA vaccination. A DNA vector containing wild type HIV-1 gag coding sequences did not induce detectable Gag expression in any of the cells tested. Attempts to increase nuclear export of Gag expression RNA by adding the constitutive transport element yielded only a moderate increase in Gag expression in monkey-derived COS cells and an even lower increase in Gag expression in HeLa cells or several mouse cell lines. In contrast, silent-site mutations in the HIV-1 gag coding sequences significantly increased Gag expression levels in all cells tested. Furthermore, this construct induced both Gag-specific antibody and CTL responses in mice after DNA vaccination. Using this construct, we achieved stable expression of HIV-1 Gag in the mouse cell line p815, which can now be used as a target cell for measuring HIV-1 Gag-specific CTL responses in immunized mice. The DNA vectors described in this study should make it possible to systematically evaluate the approaches for maximizing the induction of CTL responses against HIV-1 Gag in mouse and other animal systems.
引用
收藏
页码:9145 / 9152
页数:8
相关论文
共 50 条
  • [1] Myristoylation is required for human immunodeficiency virus type 1 gag-gag multimerization in mammalian cells
    Li, Hua
    Dou, Jun
    Ding, Lingmei
    Spearman, Paul
    JOURNAL OF VIROLOGY, 2007, 81 (23) : 12899 - 12910
  • [2] Optimization of Human Immunodeficiency Virus Gag Expression by Newcastle Disease Virus Vectors for the Induction of Potent Immune Responses
    Carnero, Elena
    Li, Wenjing
    Borderia, Antonio V.
    Moltedo, Bruno
    Moran, Thomas
    Garcia-Sastre, Adolfo
    JOURNAL OF VIROLOGY, 2009, 83 (02) : 584 - 597
  • [3] Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines
    O'Hagan, D
    Singh, M
    Ugozzoli, M
    Wild, C
    Barnett, S
    Chen, MC
    Schaefer, M
    Doe, B
    Otten, GR
    Ulmer, JB
    JOURNAL OF VIROLOGY, 2001, 75 (19) : 9037 - 9043
  • [4] Evaluation of human immunodeficiency virus type 1 subtype C gag, pol, and gagpol DNA and alphavirus replicon vaccines
    Megede, JZ
    Otten, GR
    Doe, B
    Liu, H
    Srivastava, R
    Greer, C
    Legg, H
    Tang, T
    Polo, JM
    Donnelly, JJ
    Ulmer, JB
    Barnett, SW
    VACCINE, 2006, 24 (15) : 2755 - 2763
  • [5] Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein
    Deml, L
    Bojak, A
    Steck, S
    Graf, M
    Wild, J
    Schirmbeck, R
    Wolf, H
    Wagner, R
    JOURNAL OF VIROLOGY, 2001, 75 (22) : 10991 - 11001
  • [6] Induction of immune responses to a human immunodeficiency virus type 1 epitope by novel chimeric influenza viruses
    Takizawa, Naoki
    Morita, Mayuko
    Adachi, Kei
    Watanabe, Ken
    Kobayashi, Nobuyuki
    DRUG DISCOVERIES AND THERAPEUTICS, 2009, 3 (06): : 252 - 259
  • [7] Enhancement of primary and secondary cellular immune responses against human immunodeficiency virus type 1 Gag by using DNA expression vectors that target Gag antigen to the secretory pathway
    Qiu, JT
    Liu, BD
    Tian, CJ
    Pavlakis, GN
    Yu, XF
    JOURNAL OF VIROLOGY, 2000, 74 (13) : 5997 - 6005
  • [8] DNA vaccines against human immunodeficiency virus type 1
    Estcourt, MJ
    McMichael, AJ
    Hanke, T
    IMMUNOLOGICAL REVIEWS, 2004, 199 (01) : 144 - 155
  • [9] In vitro assembly of human immunodeficiency virus type 1 Gag protein
    Morikawa, Y
    Goto, T
    Sano, K
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (39) : 27997 - 28002
  • [10] Particle size determinants in the human immunodeficiency virus type 1 Gag protein
    Garnier, L
    Ratner, L
    Rovinski, B
    Cao, SX
    Wills, JW
    JOURNAL OF VIROLOGY, 1998, 72 (06) : 4667 - 4677